Preimplantation Genetic Testing Market Set to Reach $1.2 Billion by 2031, Driven by Advances in Genetic Screening and Growing IVF Demand: Market Research Intellect [Yahoo! Finance]
Illumina announces expansion of TruSight Oncology portfolio [Yahoo! Finance]
Illumina announces expansion of TruSight Oncology portfolio
INITIATE Ventures Closes $45 Million to Fund and Co-create Companies at the Intersection of Healthcare, Life Sciences, and Tech
Illumina, Inc. (NASDAQ: ILMN) had its price target raised by analysts at Stephens from $170.00 to $184.00. They now have an "overweight" rating on the stock.